Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the safety, tolerability and to
determine the recommended Phase 2 dose (RP2D) of magrolimab (Mag) in combination with the
anti-leukemia therapies of venetoclax (Ven) and azacitidine (Aza) (Cohort 1), mitoxantrone,
etoposide, and cytarabine (MEC) (Cohort 2) and CC-486 (Cohort 3) respectively in participants
with acute myeloid leukemia (AML), to evaluate the efficacy of magrolimab in combination with
the anti-leukemia therapies as determined by the rate of complete remission (CR) (Phase 2
Cohorts 1 and 2), and/or complete remission with incomplete hematologic recovery (CRi)
(CR/CRi) (Phase 2 Cohort 2) and to evaluate the efficacy of magrolimab in combination with
anti-leukemia therapy CC-486 as determined by the minimal residual disease (MRD) negative CR
rate (Phase 2 Cohort 3).